Details
Stereochemistry | ACHIRAL |
Molecular Formula | CHO3.K |
Molecular Weight | 100.1151 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].OC([O-])=O
InChI
InChIKey=TYJJADVDDVDEDZ-UHFFFAOYSA-M
InChI=1S/CH2O3.K/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
DescriptionSources: https://www.drugs.com/dosage/sodium-bicarbonate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/10932544Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26617001 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/16864561
Sources: https://www.drugs.com/dosage/sodium-bicarbonate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/10932544
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26617001 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/3449184 | https://www.ncbi.nlm.nih.gov/pubmed/16864561
Diammonium carbonate is a salt with the chemical formula (NH4)2CO3. Since it readily degrades to gaseous ammonia and carbon dioxide upon heating, it is used as a leavening agent and also as smelling salt. Ammonium carbonate may be used as a leavening agent in traditional recipes, particularly those from northern Europe and Scandinavia (e.g. Speculoos, Tunnbröd or Lebkuchen). It also serves as an acidity regulator and has the E number E503. Ammonium carbonate is the main component of smelling salts, although the commercial scale of their production is small. Buckley's cough syrup from Canada today uses ammonium carbonate as an active ingredient intended to help relieve symptoms of bronchitis. Ammonium carbonate is also used as an emetic.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23078755 |
85.0 mM [Ki] | ||
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15357993 |
12.0 mM [Ki] | ||
Target ID: CHEMBL4789 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15664814 |
95.0 mM [Ki] | ||
Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16621537 |
0.27 mM [Ki] | ||
Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15664814 |
0.086 mM [Ki] | ||
Target ID: CHEMBL3025 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21208801 |
0.8 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | SODIUM BICARBONATE Approved UseINDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Launch Date2005 |
|||
Curative | SODIUM BICARBONATE Approved UseINDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Launch Date2005 |
|||
Primary | SODIUM BICARBONATE Approved UseINDICATIONS AND USAGE. Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Launch Date2005 |
PubMed
Title | Date | PubMed |
---|---|---|
Toxic synergism of disopyramide and hyperkalemia. | 1980 Oct |
|
Dose-response effects of atropine on pancreatic secretory response to intravenous cerulein in dogs. | 1986 |
|
Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. | 1995 Aug |
|
Role of NHE isoforms in mediating bicarbonate reabsorption along the nephron. | 2001 Dec |
|
Modification of a single tryptophan residue in human Cu,Zn-superoxide dismutase by peroxynitrite in the presence of bicarbonate. | 2001 Jul 9 |
|
Anion exchanger isoform 2 operates in parallel with Na(+)/H(+) exchanger isoform 1 during regulatory volume decrease of human cervical cancer cells. | 2002 Feb 13 |
|
[Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus]. | 2002 Feb 15 |
|
Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. | 2002 Jan |
|
HCO(3)(-)-dependent soluble adenylyl cyclase activates cystic fibrosis transmembrane conductance regulator in corneal endothelium. | 2003 May |
|
[HCO3-]-regulated expression and activity of soluble adenylyl cyclase in corneal endothelial and Calu-3 cells. | 2004 Apr 29 |
|
Endothelin-3 applied to the brain evokes opposite effects on bile secretion mediated by a central nitric oxide pathway. | 2005 Jul |
|
Effect of bicarbonate on iron-mediated oxidation of low-density lipoprotein. | 2005 Jul 26 |
|
Chloride conductance of CFTR facilitates basal Cl-/HCO3- exchange in the villous epithelium of intact murine duodenum. | 2005 Jun |
|
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. | 2007 Dec 1 |
Patents
Sample Use Guides
In cardiac arrest, a rapid intravenous dose of one to two 50 mL syringes (44.6 to 100 mEq) may be given initially and continued at a rate of 50 mL (44.6 to 50 mEq) every 5 to 10 minutes if necessary (as indicated by arterial pH and blood gas monitoring) to reverse the acidosis. Caution should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia.
In less urgent forms of metabolic acidosis. Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four-to- eight-hour period is approximately 2 to 5 mEq/kg of body weight - depending upon the severity of the acidosis as judged by the lowering of total CO2 content blood pH and clinical condition of the patient In metabolic acidosis associated with shock, therapy should be monitored by measuring blood gases, plasma osmolar'rty, arterial blood lactate, hemodynamics and cardiac rhythm. Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acid- base status of the blood. The next step of therapy is dependent upon the clinical response of the patient. If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27762345
A. thaliana var. Landsberg erecta (LER) suspension cells were treated with NaHCO3 at a final concentration of 1, 3, or 10 mM. For controls, NaNO3 (NO3 − is a macronutrient in MS media) was added in same concentration to nullify the effect of Na+ during the treatment. Furthermore, as HCO3 − induced significant pH changes of the MS media (pH 5.8), we added 50 mM (for 1 mM and 3 mM HCO3 −) and 100 mM (for 10 mM HCO3 −) MES buffer (pH 5.8) to the MS media, and the pH-stabilized MS media were used for both control and HCO3− treatments. In addition, the buffered MS media were sonicated to remove atmospheric gases prior to addition of HCO3−. Cells were incubated at 25 °C for 0, 5, 15, 30, 60, and 120 min on a shaker, and four replicates (n = 4) were generated for each data point after treatment with HCO3 − (treatment) and control. After treatment, 100 ml cells at a concentration of 3 x 10^6 ml−1 were filtered using filter paper mounted on funnels, quickly blotted dry using Kim wipes and immediately snap-frozen in liquid nitrogen and stored in a − 80 °C freezer until metabolite extraction.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-501(II)
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
EPA PESTICIDE CODE |
73508
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
913522
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
CFR |
21 CFR 184.1613
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/17/1888
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
WHO-ATC |
A12BA04
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
JECFA EVALUATION |
INS-501(II)
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
DSLD |
2911 (Number of products:61)
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000079863
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
C80938
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
POTASSIUM BICARBONATE
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
4520
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
SUB12234MIG
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
HM5Z15LEBN
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
1548134
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
DB11098
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
C026329
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
206-059-0
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
298-14-6
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
HM5Z15LEBN
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106975
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
m9000
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
34296
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID0021177
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
81862
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY | |||
|
516893
Created by
admin on Fri Dec 15 15:55:16 GMT 2023 , Edited by admin on Fri Dec 15 15:55:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD